165 related articles for article (PubMed ID: 30082492)
1. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.
van Maldegem A; Conley AP; Rutkowski P; Patel SR; Lugowska I; Desar IME; Bovée JVMG; Gelderblom H
Oncologist; 2019 Jan; 24(1):110-116. PubMed ID: 30082492
[TBL] [Abstract][Full Text] [Related]
2. Multimodality Treatment of Skull Base Chondrosarcomas: The Role of Histology Specific Treatment Protocols.
Raza SM; Gidley PW; Meis JM; Grosshans DR; Bell D; DeMonte F
Neurosurgery; 2017 Sep; 81(3):520-530. PubMed ID: 28368506
[TBL] [Abstract][Full Text] [Related]
3. Outcome of advanced, unresectable conventional central chondrosarcoma.
van Maldegem AM; Gelderblom H; Palmerini E; Dijkstra SD; Gambarotti M; Ruggieri P; Nout RA; van de Sande MA; Ferrari C; Ferrari S; Bovée JV; Picci P
Cancer; 2014 Oct; 120(20):3159-64. PubMed ID: 24995550
[TBL] [Abstract][Full Text] [Related]
4. Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study.
Xie L; Xu J; Sun X; Liu K; Li X; He F; Liu X; Gu J; Lv Z; Yang R; Tang X; Yan T; Li D; Yang Y; Dong S; Sun K; Shen D; Guo W
Cancer Manag Res; 2020; 12():3513-3525. PubMed ID: 32547189
[TBL] [Abstract][Full Text] [Related]
5. Advanced chondrosarcomas: role of chemotherapy and survival.
Italiano A; Mir O; Cioffi A; Palmerini E; Piperno-Neumann S; Perrin C; Chaigneau L; Penel N; Duffaud F; Kurtz JE; Collard O; Bertucci F; Bompas E; Le Cesne A; Maki RG; Ray Coquard I; Blay JY
Ann Oncol; 2013 Nov; 24(11):2916-22. PubMed ID: 24099780
[TBL] [Abstract][Full Text] [Related]
6. [Dedifferentiated chondrosarcoma. A study of 13 clinical cases and review of the literature].
Anract P; Tomeno B; Forest M
Rev Chir Orthop Reparatrice Appar Mot; 1994; 80(8):669-80. PubMed ID: 7638395
[TBL] [Abstract][Full Text] [Related]
7. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes.
Dickey ID; Rose PS; Fuchs B; Wold LE; Okuno SH; Sim FH; Scully SP
J Bone Joint Surg Am; 2004 Nov; 86(11):2412-8. PubMed ID: 15523011
[TBL] [Abstract][Full Text] [Related]
8. Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis.
Amer KM; Munn M; Congiusta D; Abraham JA; Basu Mallick A
J Orthop Res; 2020 Feb; 38(2):311-319. PubMed ID: 31498474
[TBL] [Abstract][Full Text] [Related]
9. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
van Oosterwijk JG; Meijer D; van Ruler MA; van den Akker BE; Oosting J; Krenács T; Picci P; Flanagan AM; Liegl-Atzwanger B; Leithner A; Athanasou N; Daugaard S; Hogendoorn PC; Bovée JV
Am J Pathol; 2013 Apr; 182(4):1347-56. PubMed ID: 23415961
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.
Jones RL; Katz D; Loggers ET; Davidson D; Rodler ET; Pollack SM
Med Oncol; 2017 Aug; 34(10):167. PubMed ID: 28852958
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.
Bui N; Dietz H; Farag S; Hirbe AC; Wagner MJ; Van Tine BA; Ganjoo K; Jones RL; Keedy VL; Davis EJ
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174084
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy for Chondrosarcoma.
Rock A; Ali S; Chow WA
Curr Treat Options Oncol; 2022 Feb; 23(2):199-209. PubMed ID: 35190971
[TBL] [Abstract][Full Text] [Related]
13. Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones.
Dierselhuis EF; Goulding KA; Stevens M; Jutte PC
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD010778. PubMed ID: 30845364
[TBL] [Abstract][Full Text] [Related]
14. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Morioka H; Takahashi S; Araki N; Sugiura H; Ueda T; Takahashi M; Yonemoto T; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Susa M; Nakayama R; Nishimoto K; Kikuta K; Horiuchi K; Kawai A
BMC Cancer; 2016 Jul; 16():479. PubMed ID: 27418251
[TBL] [Abstract][Full Text] [Related]
15. The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma.
Nota SP; Braun Y; Schwab JH; van Dijk CN; Bramer JA
Sarcoma; 2015; 2015():623746. PubMed ID: 26633939
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients.
Liu C; Xi Y; Li M; Jiao Q; Zhang H; Yang Q; Yao W
PLoS One; 2017; 12(3):e0173665. PubMed ID: 28301537
[TBL] [Abstract][Full Text] [Related]
17. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets.
El Beaino M; Hoda ST; Eldeib AJ; Masrouha K
Curr Oncol Rep; 2023 Oct; 25(10):1117-1126. PubMed ID: 37603119
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy of Carbon Ion Radiotherapy for Unresectable Chondrosarcomas.
Imai R; Kamada T; Araki N;
Anticancer Res; 2017 Dec; 37(12):6959-6964. PubMed ID: 29187480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
